CAN016 first-in-human study in advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase I/II, open-label, non-randomized, multi-center first-in-human study of CAN016 in patients with advanced solid tumors. Phase I uses accelerated titration and 3+3 dose escalation to determine the maximum tolerated dose and/or recommended phase 2 dose. Phase II will enroll roughly 20–60 patients to evaluate efficacy in HER2-expressing or HER2-mutant tumors once the RP2D is established. Eligible participants are adults with confirmed recurrent or metastatic HER2-positive or HER2-mutant solid tumors who have progressed on or are intolerant to prior therapies, with at least one measurable lesion by RECIST. The study is conducted at a single center in Beijing, under Canwell Biotech Limited as sponsor.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Provide informed consent voluntarily
2. Male or female patients ≥18 years of age.
3. Patients must have a histologically or cytologically confirmed diagnosis of recurrent or metastatic HER2 expression or mutation advanced solid tumor that has failed to or intolerable with standard treatment.

   1. For Phase I dose escalation, patients must have had progression of disease on an HER2 targeted ADC and should be refractory to or intolerant of exiting therapy(ies) known to provide clinical benefit for their condition;
   2. For Phase II, patients with advanced/unresectable or metastatic HER2 positive (IHC 3+, 2+/ISH+) breast cancer, HER2 low/ultralow expression (IHC 1+, 2+/ISH-, IHC 0 with membrane staining) breast cancer and other HER2 expression or mutation advanced solid tumors are eligible. Patients must have had progression of disease on prior HER2 targeted ADC.
4. At least one measurable lesion as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
5. Adequate organ function with 7 days before registration
6. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
7. LVEF ≥50% by either echocardiogram (ECHO) or multigated acquisition scan (MUGA) within 28 days before registration.
8. Life expectancy of ≥3 months.

Exclusion Criteria

1. Patient has received any anticancer therapy (including chemotherapy, targeted therapy, hormonal therapy, biotherapy, immunotherapy, or other investigational agents.) within 28 days or 5 times of half-lives (whichever is shorter) prior to the first dose of the study treatment or who have not recovered from the side effect of such therapy.
2. Radical radiation therapy (including radiation therapy for over 25% bone marrow) within 4 weeks prior to the first dose of the investigational product or received local palliative radiation therapy for bone metastases within 2 weeks.
3. Patients have autologous transplantation within 3 months.
4. Major surgery or had significant traumatic injury within 60 days prior to the first dose of the investigational product or has not recovered from major side effects.
5. Multiple primary malignancies within 5 years, except adequately resected non-melanoma skin cancer, curatively treated in-situ disease.
6. Any toxicities from prior treatment that have not recovered to baseline or ≤CTCAE Grade 1 before the start of study treatment, with exception of hair loss.

Where it's running

• Cancer Hospital Chinese Academy Of Medical Sciences
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Binghe Xu, MD,PhD — Cancer Institute and Hospital, Chinese Academy of Medical Sciences
• Study coordinator: Binghe Xu, MD,PhD
• Email: xubinghe@medmail.com.cn
• Phone: +86 010-67781331

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Evaluating TCC1727 tablets in patients with advanced solid tumors

  This study is testing a new oral tablet called TCC1727 to see if it can safely help people with advanced solid tumors feel better and improve their condition.

  Recruiting Phase 1/2 Beijing Tide Pharmaceutical Co., Ltd · Beijing, Beijing Municipality · NCT05970016

• PM534 treatment for patients with advanced solid tumors

  This study is testing a new treatment called PM534 to see if it is safe for people with advanced solid tumors when given through an IV.

  Recruiting at 3 sites Phase 1 PharmaMar · Barcelona and 2 other locations · NCT05835609

• Using CAN2109 to treat advanced solid tumors and lymphomas

  This study is testing a new treatment called CAN2109 that is injected directly into tumors to see if it can help people with advanced solid tumors and lymphomas feel better.

  Recruiting Phase 1 Canwell Biotech Limited · Guangzhou, Guangdong · NCT06332430

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.